Harvey D. White

from Wikipedia, the free encyclopedia

Harvey D. White is a New Zealand cardiologist .

Life

White studied medicine at the University of Otago with a Bachelor of Medicine (MB) and Bachelor of Surgery (MCh) degree in 1973. He was then a surgeon at Kew Hospital and from 1978 as a cardiologist (Cardiology Registrar) at Green Lane Hospital, Auckland City Hospital . White heads the Coronary Care and Cardiovascular Research department there.

In 1995 he received a D. Sc. at the University of Otago.

In 1987, White showed that thrombolysis therapy, which experienced an upswing especially after the publication of the GISSI study in 1986, improved the function of the left ventricle and the survival rates in acute myocardial infarction . In 1989 he compared the effectiveness of streptokinase and plasminogen for thrombolytic treatment in another study and in 1990 he demonstrated the effectiveness of repeated thrombolytic treatment after myocarditis infarcts to prevent further infarctions.

White headed the PRISM study (Platelet Receptor Inhibition for Ischemic Syndrome Management) on the administration of antagonists ( glycoprotein IIb / IIIa) for platelet receptors (for platelet aggregation ) and the HERO and HERO-2 study (Hirulog Early Reperfusion, test of the possible Advantages of the anticoagulant and hirudin analogue bivalirudin over heparin ). He is a member of the VIGOR group (Virtual Coordinating Center for Global Collaborative Cardiovascular Research) and co-leader of the group Redefinition of Myocardial Infarction of the European Society of Cardiology and the American Heart Association .

He is an honorary professor at the University of Auckland.

In 1998 he received the Prince Mahidol Prize .

Web links

Individual evidence

  1. ^ Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study . Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). In: The Lancet , 1987, p. 871. Sikri, Bardia: A history of Streptokinase Use in Acute Myocardinal Infarction. In: Texas Heart Institute Journal. Volume 34, 2007, p. 318, PMC 1995058 (free full text).
  2. ↑ White, Norris, Brown, et al. a .: Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. In: New England J. Medicine. Volume 317, 1987, p. 815.
  3. ↑ Harvey D. White, Frans JJ van de Werf: Thrombolysis for acute myocardial infarction. In: Circulation. Volume 97, 1998, p. 1632, circ.ahajournals.org ( Memento of the original from May 28, 2011 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / circ.ahajournals.org
  4. ↑ HD White, J. Rivers, A. Maslowski et al. a .: Effect of intravenous streptokinase as compared with that of tissue plasminogen activator in left ventricular function after first myocardial infarction. In: New England J. Med. Volume 320, 1989, pp. 817-821.
  5. ^ HD White, DB Cross, BF Williams, RM Norris: Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. In: British Heart J. Volume 64, 1990, p. 177. Abstract
  6. ↑ HD White: Newer antiplatelet agents in acute coronary syndromes. In: Am. Heart Journal. Volume 138, 1999, p. 570, PMID 10577464 .
  7. ↑ Hirulog, Angiomax, Angiox. Manufacturer The Medicines Company. German Heart Center 2010 on Bivalirudin ( Memento of the original dated February 12, 2009 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / www.dhzb.de
  8. ↑ HD White u. a .: Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO). In: Circulation. Volume 96, 1997, p. 2155, circ.ahajournals.org  ( page no longer available , search in web archives )  Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice.@1@ 2Template: Toter Link / circ.ahajournals.org  
  9. ↑ HD White u. a .: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomized trial. In: The Lancet . Volume 358, 2001, p. 1855. In addition, Fran Lowry: HERO-2: Bivalirudin compared to heparin in AMI patients receiving streptokinase. September 3, 2001.
personal data
SURNAME White, Harvey D.
BRIEF DESCRIPTION New Zealand medic
DATE OF BIRTH 20th century